Aya Gold & Silver Secures US$25 Million Credit Facility from EBRD to Support Growth in Morocco
MONTREAL, May 12, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) ('Aya' or the 'Corporation') is pleased to announce that it has received final internal approval by the Board of Directors of the European Bank for Reconstruction and Development ('EBRD'), for a proposed US$25 million secured credit facility (the 'Facility'). The proceeds of the Facility are intended to support the development of the Corporation's Boumadine polymetallic project and enhance financial flexibility as part of Aya's growth strategy in Morocco.
This Facility from EBRD, the current lender on the Zgounder Silver Mine expansion project, represents a significant endorsement of Aya's operating and financial track record and further strengthens the Company's long-standing relationship with EBRD, who has been a strategic partner in Morocco.
'As a responsible operator committed to sustainable growth, we are pleased to welcome this non-dilutive credit facility from EBRD,' said Benoit La Salle, President and CEO of Aya Gold & Silver. 'It is a strong endorsement of our leadership position in Morocco and the trusted partnerships we've built. With robust free cash flow and a strengthening balance sheet, we are well equipped to accelerate our growth plan and deliver low-cost ounces at Boumadine and Zgounder.'
'We are pleased to strengthen our 10-year partnership with Aya Gold & Silver, whose operational progress, growth plans, and focus on sustainability are well aligned with our priorities,' said Natalia Lacorzana, Head of Natural Resources, EBRD. 'Since our last project finance facility in 2023, Aya has made steady progress at Zgounder and advanced the potential of Boumadine. This new facility reflects our confidence in the company's leadership and our continued support for responsible mining in Morocco.'
The Facility remains subject to: (i) negotiation and finalization of definitive agreements; and (ii) customary closing conditions, including security arrangements and regulatory compliance.
The proposed two-year term Facility is expected to be structured as a secured bullet payment loan with a 5.00% interest margin, semi-annual interest payments, and customary fees.
The Facility will be used to support Aya's balance sheet and continue the development of its high-grade Boumadine polymetallic project.
About Aya Gold & Silver Inc.
Aya Gold & Silver Inc. is a rapidly growing, Canada-based silver producer with operations in the Kingdom of Morocco.
The only TSX-listed pure silver mining company, Aya operates the high-grade Zgounder Silver Mine and is exploring its properties along the prospective South-Atlas Fault, several of which have hosted past-producing mines and historical resources.
Aya's management team has been focused on maximizing shareholder value by anchoring sustainability at the heart of its operations, governance, and financial growth plans.
For additional information, please visit Aya's website at
www.ayagoldsilver.com
.
Or contact
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws ('forward-looking statements'), which reflects management's expectations regarding Aya's future and business prospects. Wherever possible, words such as 'intend', 'enhance', 'growth', 'strengthen', 'ensure', 'plan', and similar expressions or statements that certain actions, events or results 'may', 'could', 'would', 'might', 'will', or are 'likely' to be taken, occur or be achieved, have been used to identify such forward-looking information. Specific forward-looking statements in this press release include, but are not limited to, statements and information with respect to Aya's strength of the balance sheet, its growth plans, the continued execution on its strategic plans, its ability to become a leading silver producer in the region. Such statements reflect the Corporation's views as at the date of this press release and are subject to certain risks, uncertainties and assumptions, and undue reliance should not be placed on such statements. Although the forward-looking information contained in this press release reflect management's current beliefs based upon information currently available to management and based upon what management believes to be reasonable assumptions, Aya cannot be certain that actual results will be consistent with such forward-looking information.
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Corporation as of the date of such statements, are inherently subject to significant business, geological, economic and competitive uncertainties and contingencies. The material factors and assumptions used in the preparation of the forward-looking statements contained herein, which may prove to be incorrect, include, but are not limited to Aya's capacity to execute on its plan, its capacity to achieve each item of its guidance, and those material factors and assumptions set forth in Corporation's management's discussion and analysis ('MD&A') and the Corporation's Annual Information Form ('AIF') for the year ended December 31, 2024 available with Canadian securities regulators. For a more detailed discussion of such risks and other factors that may affect the Corporation's ability to achieve the expectations set forth in the forward-looking statements contained in this press release, see the AIF and MD&A available on SEDAR+ at
www.sedarplus.ca
, as well as the Corporation's other filings with the Canadian securities regulators.
Readers are advised and cautioned not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Corporation undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Qualcomm Agrees to Buy Chip Firm Alphawave for $2.4 Billion
(Bloomberg) -- Qualcomm Inc. has agreed to buy London-listed semiconductor company Alphawave IP Group Plc for about $2.4 billion in cash to expand its technology for artificial intelligence. Next Stop: Rancho Cucamonga! Where Public Transit Systems Are Bouncing Back Around the World Trump Said He Fired the National Portrait Gallery Director. She's Still There. ICE Moves to DNA-Test Families Targeted for Deportation with New Contract US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn The offer equates to about 183 pence per share for Alphawave, the companies said in a statement on Monday. That's a 96% premium to the company's share price on March 31, the last trading day before Alphawave and Qualcomm disclosed the talks. The deal, which is still subject to regulatory and shareholder approval, is expected to close in the first quarter of 2026. Qualcomm Chief Executive Officer Cristiano Amon is looking to lessen the company's reliance on the smartphone market, where growth has slowed, and push into new areas. Alphawave makes high-speed semiconductor and connectivity technology that can be used for data centers and AI applications, two growth areas in the chip industry that are being driven by demand for products like OpenAI's ChatGPT. Alphawave's board has unanimously recommended the cash offer. Investors representing 75% of shares must vote in favor of the deal for it to go through. Alphawave shareholders and directors representing about 50% of shares have agreed to vote in favor of the deal, the company said. Alphawave shares rose 23% to 183.60 pence at 8:53 a.m. in London. The shares have risen about 117% this year. Alphawave, which held an initial public offering in 2021 at 410 pence per share, has consistently traded below that level. The company had struggled with a reliance on large customers and navigating geopolitical tensions between the US and China, where Alphawave decided to cut back its business last year. Still, the company's technology has been gaining traction and had reported a surge in orders in the fourth quarter. Chief Executive Officer Tony Pialis said in a statement at the time that orders from North American AI customers were driving the business. As an alternative to the cash offer, Alphawave shareholders can also opt to exchange their stock for 0.01662 shares of Qualcomm. Qualcomm has also said that each Alphawave share could be exchanged for 0.00964 of a new 'series A Qualcomm exchangeable security' and 0.00698 of a new 'series B Qualcomm exchangeable security.' The Alphawave directors declined to recommend the alternative offers. In particular, they said they're unable to declare whether the second alternative deal, where shareholders trade stock for exchangeable securities, is fair and reasonable 'given the significant and variable impact of the advantages and disadvantages.' (Updates with premium in second paragraph) The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again Is Elon Musk's Political Capital Spent? What Does Musk-Trump Split Mean for a 'Big, Beautiful Bill'? Cuts to US Aid Imperil the World's Largest HIV Treatment Program ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Allego Launches World-First Most Secure Plug & Charge Technology
Charging, the way it should be. Allego Holiday Couple Arnhem, Netherlands, June 09, 2025 (GLOBE NEWSWIRE) -- Allego is the first in the world to launch the most secure version of Plug & Charge technology built on the latest OCPP 2.0.1 protocol. The Plug & Charge technology allows drivers to automatically authenticate and pay when plugging in, eliminating the need for RFID cards, bank cards, or mobile apps, giving a smoother customer experience. The Plug & Charge technology utilizes certificate-based authentication with encrypted communication, providing users with the market's most secure and tamper-proof charging sessions. Allego launches Plug & Charge across its extensive Fast and Ultra-fast European charging network today on June 9th, 2025. ARNHEM, Netherlands – June 9, 2025—Allego N.V. ('Allego' or the 'Company'), a leading provider of electric vehicle charging solutions, today launched Europe's first rollout of the world's safest and most secure Plug & Charge technology. This technology makes charging as simple as plugging in your car. Based on the open industry standard OCPP 2.0.1, Allego is the first operator worldwide to deliver a cross-network solution that provides seamless, secure, and reliable charging for all compatible electric vehicle models. 'Our mission is to make EV charging at Allego the most intuitive,' said Jean Gadrat, Chief Marketing Officer at Allego. 'By removing digital friction points, apps, and cards, we give drivers the confidence to travel further and charge more conveniently. Whether in the city, on the highway, or abroad, Plug & Charge delivers the same secure, one-step charging experience.' Plug & Charge is an ISO 15118-based authentication and payment method built by Allego on OCPP 2.0.1, the industry's most advanced charger-to-back-end protocol. It standardizes communication between any OCPP-compliant charger and network. Plug & Charge works seamlessly at any of Allego's 5000 Fast and Ultra-fast charge points and partner networks across Europe. The Plug & Charge technology creates a truly seamless driver experience. When a compatible EV is plugged in, the vehicle and charger automatically exchange encrypted digital certificates to identify the driver's account and initiate charging. No apps, RFID tokens, or manual interventions are required. Drivers have effortless access: after following your in-vehicle and app steps to enable your car for Plug & Charge, plug in, and your EV takes care of the rest. The charging session begins instantly without requiring any additional steps. Mutual Transport Layer Security (TLS) and certificate-based authentication guarantee that only authorized vehicles can charge, protecting drivers from billing errors or fraudulent access. 'This results in future-proof technology,' said Manuel Trotta, Head of Mobility Solutions at Allego. 'As new vehicle models and charging technologies emerge, OCPP 2.0.1 supports remote firmware updates, new features, and secure certificate management, ensuring your car always 'speaks the same language' as the charger.' This rollout was made possible through Allego's collaboration with industry leaders, including Alpitronic, Hubject, and Ford. It is part of Allego's ongoing efforts to innovate and enhance the electric vehicle charging experience, reinforcing its position as a leader in the e-mobility industry. For full details on Plug & Charge, including compatible vehicles, station finders and FAQs, please visit: xxx About Allego Allego is a market-leading provider of electric vehicle charging infrastructure. Allego is dedicated to accelerating the transition to electric mobility using 100% renewable energy. With a network of over 35,000 charging points spanning more than 16 countries, Allego delivers sustainable, independent, reliable, and safe charging solutions to EV drivers across Europe, agnostic of vehicle model or network affiliation. For more information, please visit Allego Contact: Mediapress@ Attachment Allego Holiday Couple CONTACT: Meliska Schupp Allego N.V.
